1. Saxagliptin improves glycemic control in younger and older individuals with type 2 diabetes.
Saxagliptin improves glycemic control in younger and older individuals with type 2 diabetes. Temporal achievement rates for HbA1c <7.0% (53.0 mmol/mol) (A) and HbA1c ≤6.5% (47.5 mmol/mol) (B). Participants randomized to the saxagliptin arm received either 5 mg daily or 2.5 mg daily if they had an eGFR ≤50 mL/min/1.73 m2. Median follow-up was 2.1 years. *P < vs. corresponding placebo group. P, placebo; S, saxagliptin.
Lawrence A. Leiter et al. Dia Care 2015;38:
©2015 by American Diabetes Association